KYRON.BIO

We are using a novel glycan engineering approach to deliver better therapeutics to

those most in need. We engineer drugs by controlling the addition of glycans – essential

sugar molecules found on the surface of drugs – to enhance drug specificity, activity, and

longevity. We have developed a proprietary technology to control the glycans added to

drugs and have a patent pending.

We are a dynamic, international, early-stage startup backed by Entrepreneur First, the

world’s leading talent investor, along with European and US investors. We have

established collaborations with KOLs across the globe and is advised by leading professors in

the field and a former Sanofi VP. We have recently won numerous prestigious research

grants including the iLab Concours d'Innovation (BPI France), the Women TechEU (European

Innovation Commission), and Innov'up Leader PIA (BPI France).